Having observed marked reductions in experimental liver metastases in mice with sustained high plasma levels of an IGF-IR decoy, and in an effort to expedite potential translation of this technology to the clinic, we used recombinant technology to engineer and scale-up production of an IGF-Trap with potent anti-cancer activity. This evidence concerns the gene IGF1R and cancer.